GLP-1 receptor agonists have therapeutic potential far beyond diabetes, with emerging benefits for cardiovascular health, neuroprotection, weight management, and musculoskeletal health.
6+ organ systems with GLP-1 receptorsGLP-1 receptors are found in the brain, lungs, heart, pancreas, stomach, and endometrium, explaining why these drugs have therapeutic effects beyond blood sugar control.
What the researchers found
GLP-1 receptors are widely distributed across multiple organ systems — brain, lungs, pancreas, stomach, heart, and endometrium — which explains the broad therapeutic potential of GLP-1 receptor agonists beyond their original diabetes indication.
Recent studies demonstrate physiological effects across these organ systems: blood glucose regulation and pancreatic beta-cell function, weight management through appetite suppression and metabolic effects, cardiovascular protection including reduced major adverse cardiovascular events, potential neuroprotective effects relevant to neurodegenerative diseases, and positive influences on musculoskeletal health. While clinical efficacy for diabetes and obesity is well established, many of these expanded indications are still being investigated.
Why it matters
GLP-1 receptor agonists have become one of the most prescribed drug classes globally, and understanding their full therapeutic potential is crucial for maximizing patient benefit. This review provides a broad overview of where these drugs might help beyond diabetes — from protecting the heart and brain to supporting bone health — helping clinicians and patients understand the possible additional benefits of treatments they may already be taking.
How the study worked
This is a comprehensive narrative review synthesizing recent published studies on the expanding therapeutic applications of GLP-1 receptor agonists. The review examines the physiological rationale (GLP-1 receptor distribution), clinical evidence across multiple organ systems, and identifies gaps in the current evidence base including long-term safety and cost-effectiveness data.
What this study cannot tell us
As a narrative review, the article is subject to selection bias in which studies are highlighted. Many of the expanded therapeutic applications discussed (neuroprotection, musculoskeletal health) are based on preclinical data or early-stage clinical evidence, not definitive large-scale trials. The review acknowledges significant gaps in long-term safety data and cost-effectiveness research. It does not provide a systematic or quantitative analysis of the evidence.
How to read the evidence
This is a narrative review that synthesizes existing literature across multiple therapeutic areas. While useful for providing a comprehensive overview, it does not perform systematic analysis or meta-analysis. The strength of evidence varies greatly across the different therapeutic applications discussed — some are well-established (diabetes, obesity, cardiovascular) while others are preliminary.
When this study was published
Published in 2025, this is a very current review capturing the rapidly expanding understanding of GLP-1 receptor agonist applications across multiple medical specialties.
The bigger picture
The story of GLP-1 receptor agonists illustrates how understanding a single peptide pathway can unlock treatments for multiple diseases. Originally a diabetes drug class, GLP-1RAs now represent a potential therapeutic platform for obesity, cardiovascular disease, MASH/NAFLD, neurodegenerative conditions, and more. This expansion mirrors the history of other peptide-based drugs like insulin and botulinum toxin, where a single molecule's biology proved far richer than initially appreciated.
Questions still open
- Which of the many emerging GLP-1RA applications will be supported by definitive randomized clinical trials and receive regulatory approval?
- What are the long-term safety implications of chronically activating GLP-1 receptors across multiple organ systems?
- How can GLP-1RA therapy be made more cost-effective and accessible, particularly in low- and middle-income countries?
Common questions
Can GLP-1 drugs help with conditions beyond diabetes and weight loss?
Why do GLP-1 drugs affect so many different organs?
Read the original research
Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review.
Frontiers in clinical diabetes and healthcare, 6, 1590530
Citation
Hammad, Bisma Fatima; Zafar, Nimrah; Ullah, Muneeb; Faisal, Syeda Jazilah; Iftikhar, Fizzah; Waheed, Haadia; Muzaffar, Muhammad Waleed; Ahmed, Khadija; Ashraf, Faz; Zahid, Komal; Akhtar, Maimoona; Mahmmoud Fadelallah Eljack, Mohammed. (2025). Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review.. Frontiers in clinical diabetes and healthcare, 6, 1590530. https://doi.org/10.3389/fcdhc.2025.1590530